Croda stock soars 25% as Volufiline treats Ozempic face trend
Croda, a century-old British chemical company, reversed years of declining stock after discovering its dormant ingredient Volufiline treats "Ozempic face" caused by weight-loss drugs. Revenue from the skin-plumping product surged 270 percent in the first half of 2025 as over 150 cosmetics firms adopted it, with Estée Lauder leading demand. The windfall has pushed Croda shares up 25 percent.
Take it further — get the full app and never miss a moment of what's happening in Australia.
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
Published 19 Oct 2026, 00:11 UTC · Updated 19 Oct 2026, 00:20 UTC
Summary by OZbrief Editorial. Original report: SMH. Editorial policy · Corrections
Trending
- Coroner suspends Marilyn Wallman inquest after new witness emerges in 1972 case
- Exclusive Brethren leaders admit meeting Trump and far-right agitators in inquiry
- UAE resumes Yemen payments as Gulf allies unite against Houthi advances
- Zerra DC proposes $32 billion data centre complex in Queensland with 1,500
- Jockey Jye McNeil escapes serious injury in Caulfield Cup fall, horse euthanized
- La Trobe Financial sells $31.2 million loan facility to 360 Capital